CN105228644B - 预防与免疫治疗阿尔茨海默型痴呆的肽疫苗 - Google Patents

预防与免疫治疗阿尔茨海默型痴呆的肽疫苗 Download PDF

Info

Publication number
CN105228644B
CN105228644B CN201380076473.3A CN201380076473A CN105228644B CN 105228644 B CN105228644 B CN 105228644B CN 201380076473 A CN201380076473 A CN 201380076473A CN 105228644 B CN105228644 B CN 105228644B
Authority
CN
China
Prior art keywords
peptide
vaccine
seq
beta
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380076473.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN105228644A (zh
Inventor
王长怡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Brain Science
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Priority to CN201810667175.6A priority Critical patent/CN108794615A/zh
Publication of CN105228644A publication Critical patent/CN105228644A/zh
Application granted granted Critical
Publication of CN105228644B publication Critical patent/CN105228644B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201380076473.3A 2013-03-15 2013-04-23 预防与免疫治疗阿尔茨海默型痴呆的肽疫苗 Active CN105228644B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810667175.6A CN108794615A (zh) 2013-03-15 2013-04-23 预防与免疫治疗阿尔茨海默型痴呆的肽疫苗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/843,883 US9102752B2 (en) 2013-03-15 2013-03-15 Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
US13/843,883 2013-03-15
PCT/US2013/037865 WO2014143087A1 (en) 2013-03-15 2013-04-23 Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810667175.6A Division CN108794615A (zh) 2013-03-15 2013-04-23 预防与免疫治疗阿尔茨海默型痴呆的肽疫苗

Publications (2)

Publication Number Publication Date
CN105228644A CN105228644A (zh) 2016-01-06
CN105228644B true CN105228644B (zh) 2018-07-13

Family

ID=51527985

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380076473.3A Active CN105228644B (zh) 2013-03-15 2013-04-23 预防与免疫治疗阿尔茨海默型痴呆的肽疫苗
CN201810667175.6A Pending CN108794615A (zh) 2013-03-15 2013-04-23 预防与免疫治疗阿尔茨海默型痴呆的肽疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810667175.6A Pending CN108794615A (zh) 2013-03-15 2013-04-23 预防与免疫治疗阿尔茨海默型痴呆的肽疫苗

Country Status (18)

Country Link
US (4) US9102752B2 (enExample)
EP (1) EP2968485B1 (enExample)
JP (3) JP6208319B2 (enExample)
KR (2) KR101926030B1 (enExample)
CN (2) CN105228644B (enExample)
AU (3) AU2013381835A1 (enExample)
BR (1) BR112015023105A8 (enExample)
CA (1) CA2906313A1 (enExample)
DK (1) DK2968485T3 (enExample)
ES (1) ES2800028T3 (enExample)
IL (2) IL241597B (enExample)
MX (2) MX364689B (enExample)
PT (1) PT2968485T (enExample)
RU (1) RU2696566C2 (enExample)
SG (1) SG11201507669YA (enExample)
TW (1) TWI561529B (enExample)
WO (1) WO2014143087A1 (enExample)
ZA (2) ZA201507526B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
CA2948283A1 (en) * 2014-04-07 2015-10-15 Merganser Biotech, Inc. Hepcidin mimetic peptides and uses thereof
WO2017131468A1 (ko) * 2016-01-27 2017-08-03 경상대학교산학협력단 아디포넥틴 수용체 활성화 신규 펩티드를 유효성분으로 포함하는 신경질환의 예방, 개선 또는 치료용 조성물
EP3444344A4 (en) * 2016-04-14 2020-02-19 TAO Health Life Pharma Co., Ltd. AMYLOSPHEROID TYPE STRUCTURE (ASPD) AND PHARMACEUTICAL COMPOSITION
CN106565847B (zh) * 2016-10-26 2020-12-01 清华大学 化合物、多肽及其用途
US20210138049A1 (en) * 2017-06-16 2021-05-13 United Neuroscience Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies
WO2019084488A1 (en) 2017-10-27 2019-05-02 United Neuroscience IMMUNOGENIC CONSTRUCTS OF PEPTIDE TAU
SG11202005526WA (en) * 2017-12-11 2020-07-29 Ubi Ip Holdings Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
RU2769983C2 (ru) * 2017-12-31 2022-04-12 Юнайтед Байомедикал, Инк. ПЕПТИДНЫЕ ИММУНОГЕНЫ И СОДЕРЖАЩИЕ ИХ СОСТАВЫ, НАЦЕЛЕННЫЕ НА МЕМБРАНОСВЯЗАННЫЕ IgE ДЛЯ ЛЕЧЕНИЯ ОПОСРЕДОВАННЫХ IgE АЛЛЕРГИЧЕСКИХ ЗАБОЛЕВАНИЙ
AU2019222707A1 (en) * 2018-02-13 2020-08-13 Cedars-Sinai Medical Center Methods and systems for identification and treatment of pathological neurodegeneration and age-related cognitive decline
CA3095983A1 (en) 2018-04-10 2019-10-17 Ac Immune Sa Anti-abeta therapeutic vaccines
CA3099296A1 (en) * 2018-05-04 2019-11-07 Ubi Ip Holdings Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
TWI676635B (zh) * 2018-06-15 2019-11-11 英屬開曼群島商聯腦科學公司 α－突觸核蛋白Ｃ端胜肽免疫原及其用於治療突觸核蛋白疾病的配方
JP7505788B2 (ja) * 2018-10-01 2024-06-25 ユナイテッド ニューロサイエンス Ｃ９ｏｒｆ７２に由来するジペプチドリピートタンパク質に対して指向化されたペプチド免疫原コンストラクト
PH12021551462A1 (en) * 2018-12-19 2022-04-11 Ubi Ip Holdings Artificial promiscuous t helper cell epitopes as immune stimulators for synthetic peptide immunogens
MX2021007906A (es) 2018-12-28 2021-10-13 United Biomedical Inc Nmunógenos peptídicos dirigidos a la interleucina 6 (il-6) y sus formulaciones para la inmunoterapia de enfermedades afectadas por la desregulación de la il-6.
US20220073582A1 (en) * 2018-12-31 2022-03-10 United Neuroscience Limited Peptide immunogens targeting calcitonin gene-related peptide (cgrp) and formulations thereof for prevention and treatment of migraine
CN110759987B (zh) * 2019-10-29 2021-06-08 中国人民解放军军事科学院军事医学研究院 构象特异性的重组Aβ1-42样寡聚体抗原、其制备方法和应用
EP4093756A4 (en) * 2020-01-23 2024-06-12 United Biomedical Inc. Peptide immunogens targeting pituitary adenylate cyclase-activating peptide (pacap) and formulations thereof for prevention and treatment of migraine
EP4118111A1 (en) 2020-03-10 2023-01-18 LifeArc Cyclic peptides
AU2021385036A1 (en) 2020-11-17 2023-06-08 Iliad Biotechnologies, Llc Treatment and prevention of neuropathology associated with neurodegenerative diseases
WO2022197651A1 (en) * 2021-03-16 2022-09-22 Neurovision Imaging, Inc. Biofluid-based methods for diagnosing alzheimer's disease-associated conditions
US20240358805A1 (en) * 2021-08-30 2024-10-31 The Brigham And Women's Hospital, Inc. Methods and materials to treat neurodegenerative disease
US20250057928A1 (en) 2021-12-08 2025-02-20 Osaka University Vaccine composition for inducing anti-il-23 antibody
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN115417915B (zh) * 2022-11-03 2023-02-24 北京引正基因科技有限公司 多肽载体及其应用
CN117122612B (zh) * 2023-07-07 2024-08-27 河络新图生物科技(上海)有限公司 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
WO1991016819A1 (en) 1990-04-27 1991-11-14 Molecular Rx., Inc. Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
WO1994028412A1 (en) 1993-05-28 1994-12-08 The Miriam Hospital Composition and method for in vivo imaging of amyloid deposits
CA2175579A1 (en) 1993-10-26 1995-05-04 Chang Yi Wang Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6025468A (en) 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
DE60044057D1 (de) 1999-09-03 2010-05-06 Univ Ramot Verbindungen, zusammensetzungen und verfahren zur behandlung oder vorsorge von alzheimer erkrankung
ATE344803T1 (de) 1999-12-08 2006-11-15 Intellect Neurosciences Inc Schimärische amyloid-beta peptide
US20030165481A1 (en) 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US20030083277A1 (en) * 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
EP1911765A3 (en) * 2002-07-24 2008-04-23 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation
EP1711208A2 (en) * 2004-01-28 2006-10-18 Curix APS Conjugates of amyloid proteins as vaccines for amyloid-related diseases
JP5097695B2 (ja) * 2006-02-22 2012-12-12 株式会社林原 抗アミロイドβペプチド抗体産生誘導用のペプチドワクチン
CN101384279B (zh) * 2006-02-24 2012-02-22 奇斯药制品公司 抗淀粉样蛋白免疫原性组合物、方法和用途
US20090123488A1 (en) * 2006-08-14 2009-05-14 Thymon, Llc Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
AT506820B1 (de) 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
CA2736729A1 (en) * 2008-09-29 2010-04-01 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
US9067981B1 (en) * 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2012056008A1 (en) * 2010-10-28 2012-05-03 Jonas Nilsson Diagnosis and treatment of alzheimer's disease
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type

Also Published As

Publication number Publication date
US20180244739A1 (en) 2018-08-30
EP2968485A1 (en) 2016-01-20
EP2968485A4 (en) 2016-09-07
RU2019123453A (ru) 2019-09-10
CN105228644A (zh) 2016-01-06
BR112015023105A2 (pt) 2017-11-21
HK1212600A1 (zh) 2016-06-17
JP2019196397A (ja) 2019-11-14
AU2019246916A1 (en) 2019-10-31
TWI561529B (en) 2016-12-11
AU2013381835A1 (en) 2015-10-08
WO2014143087A1 (en) 2014-09-18
KR20150132396A (ko) 2015-11-25
RU2696566C2 (ru) 2019-08-05
AU2017203425A1 (en) 2017-06-08
ES2800028T3 (es) 2020-12-23
JP2016513638A (ja) 2016-05-16
CA2906313A1 (en) 2014-09-18
US20160068581A1 (en) 2016-03-10
KR101926030B1 (ko) 2018-12-10
PT2968485T (pt) 2020-06-26
TW201434478A (zh) 2014-09-16
IL265910A (en) 2019-06-30
JP2017226646A (ja) 2017-12-28
JP6208319B2 (ja) 2017-10-04
KR20180132962A (ko) 2018-12-12
MX364689B (es) 2019-05-06
JP6784646B2 (ja) 2020-11-11
EP2968485B1 (en) 2020-03-04
US20190194280A1 (en) 2019-06-27
CN108794615A (zh) 2018-11-13
MX2019005268A (es) 2019-07-01
BR112015023105A8 (pt) 2018-01-23
IL241597B (en) 2020-07-30
RU2015142996A (ru) 2017-04-24
ZA201906683B (en) 2023-04-26
DK2968485T3 (da) 2020-06-08
US20140271690A1 (en) 2014-09-18
ZA201507526B (en) 2019-12-18
AU2017203425B2 (en) 2019-07-11
SG11201507669YA (en) 2015-10-29
MX2015013235A (es) 2016-04-04
US9102752B2 (en) 2015-08-11

Similar Documents

Publication Publication Date Title
CN105228644B (zh) 预防与免疫治疗阿尔茨海默型痴呆的肽疫苗
KR102799692B1 (ko) 타우 펩타이드 면역원 작제물
TWI741241B (zh) 用於治療及/或預防異位性皮膚炎之il-31胜肽免疫原及其劑型
WO2013003579A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection
JPH09502346A (ja) 自己免疫疾患に関連するプロトコールにおけるミエリン希突起神経膠細胞糖蛋白質およびそのペプチド部分の使用
JP2022515934A (ja) カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）を標的とするペプチド免疫原ならびに片頭痛の治療及び予防のためのそれらの配合物
JP2023519104A (ja) 凝集膵島アミロイドポリペプチド（ｉａｐｐ）と関連する障害を予防及び治療するための、ｉａｐｐを標的とするペプチド免疫原
TW202438516A (zh) TAU及β類澱粉肽免疫原組合物及相關方法
US20220023401A1 (en) Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type
RU2811687C2 (ru) Пептидная вакцина для предупреждения и иммунотерапии деменции альцгеймеровского типа
TWI609026B (zh) 抑制與免疫治療阿茲海默型癡呆的胜肽疫苗
HK1212600B (zh) 預防與免疫治療阿爾茨海默型癡呆的肽疫苗
KR20240110105A (ko) Ige 매개 알레르기 질환의 치료를 위한 막 결합 ige를 표적하는 펩티드 면역원 및 이의 제제

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1212600

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240719

Address after: Cayman Islands

Patentee after: United Brain Science

Country or region after: Cayman Islands

Address before: USA New York

Patentee before: United Biomedical, Inc.

Country or region before: U.S.A.